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Subclinical Inflammation During Third Trimester of Pregnancy
Was Not Associated with Markers of the Metabolic Syndrome
in Young Adult Offspring
Inge Danielsen1,2, Charlotta Granstr€om2, Dorte Rytter3, Thorhallur I. Halldorsson2,4, Bodil Hammer Bech3,
Tine Brink Henriksen5, Coen D. A. Stehouwer6, Casper G. Schalkwijk6, Allan A. Vaag1,7 and Sjurdur F. Olsen2
Objective: Growing evidence indicates that the metabolic syndrome (MS) is rooted in adverse exposures
during fetal life. The aim of this study was to assess the possible associations between biomarkers of
inflammation during third trimester of pregnancy and markers of MS in adult offspring.
Methods: High-sensitive C-reactive protein (CRP), tumor necrosis factor-a (TNF-a), interleukin-1b (IL-1b)
and interleuki-6 (IL-6) were measured in serum samples obtained in gestational week 30. Offspring were
clinically examined at age 20 years. Analyses based on 439 mother–offspring dyads were adjusted for
maternal smoking during pregnancy, height, prepregnancy body mass index (BMI), education, and
offspring’s sex. Offspring MS markers included waist circumference, BMI, blood pressure, HOMA
insulin resistance, and plasma levels of fasting glucose, triglycerides, cholesterol fractions, insulin, and
leptin.
Results: The median level was 2.8 (interquartile range5 3.3) mg/ml for CRP, for TNF-a: 5.7 (3.2) pg/ml, for
IL-1b: 0.5 (0.4) pg/ml, and for IL-6: 1.1 (0.7) pg/ml. Concentrations were not significantly associated with
MS markers in the offspring. The results remained essentially unchanged after correction for potential
confounding.
Conclusion: Markers for subclinical inflammation in third trimester in healthy women were not associated
with components of MS in their adult offspring.
Obesity (2014) 22, 1351-1358. doi:10.1002/oby.20650
Introduction
Mounting evidence suggests that adverse exposures in pregnancy,
for instance obesity, diabetes and lifestyle factors, such as diet,
smoking and physical activity, are involved in developmental pro-
gramming of type 2 diabetes. Although low birth weight and diabe-
tes in pregnancy represent the most well-established factors linking
exposures during pregnancy with subsequent risk of diabetes and the
metabolic syndrome (MS) among offspring (1), we lack knowledge
about the distinct molecular mechanisms involved.
Subclinical inflammation is commonly present in patients with meta-
bolic diseases, and inflammatory markers, such as CRP, TNF-a, IL-
6, and IL-1b are associated with risk factors for chronic noncommu-
nicable diseases, including type 2 diabetes (2-7). In addition, CRP
and proinflammatory cytokines have been demonstrated to predict
future development of type 2 diabetes (8,9). Interestingly, nondia-
betic offspring of type 2 diabetic mothers were found to display ele-
vated levels of CRP and inflammatory cytokines (10). Furthermore,
it has been suggested that inflammation during pregnancy may play
a role in the programming of obesity among offspring (11).
MS, which consists of the components central obesity, reduced HDL
cholesterol and raised triglyceride levels, as well as raised blood
pressure and plasma glucose levels (12), is associated with increased
risk of cardiovascular disease and type 2 diabetes (13). Growing evi-
dence links maternal MS, obesity, and diabetes during pregnancy
with an increased risk among the offspring of developing diabetes
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and MS (14,15). Interestingly, a recent study found positive correla-
tions between maternal and fetal levels of leptin and adiponectin
and in addition a negative association between fetal leptin levels and
fetal insulin sensitivity suggesting a possible maternal–fetal trans-
mission of the propensity to obesity and insulin resistance (16). It is
still unknown if markers of early or acute inflammation in pregnant
women can predict the metabolic profile of the offspring later in
life.
Pregnancy in itself is an inflammatory state (17,18). The level of
inflammation in pregnancy has been associated with preeclampsia
(19,20), preterm birth, and/or intrauterine growth restriction (21-23),
conditions that may have adverse long-term consequences for health
(24,25).
We do not know of any previous studies of the possible associations
between inflammatory markers in pregnancy and the adult off-
spring’s metabolic profile, and we, therefore, studied this potentially
important issue in a unique Danish birth cohort with 20 years’ fol-
low-up.
Methods
The Danish Fetal Origin Cohort 1988
Nine hundred and sixty-five out of 1,212 eligible women with singleton
pregnancies were recruited for a birth cohort study in Denmark in 1988
(26). By means of a self-administered questionnaire completed by the
women prior to the antenatal visit in gestation week 30, information
about medical history as well as socioeconomic factors was gained and
supplemented by an interviewer-guided questionnaire following the
antenatal visit. Provided consent was given, a blood sample was taken
and processed under-standardized conditions. The vials were kept on
ice and within an hour separated into serum, plasma, and erythrocytes
that were frozen and stored at 220C. Further information about the
women’s health, medical history, anthropometry, and birth outcomes
was extracted from hospital records and from the Danish Medical Birth
Registry as well as from the records kept by the midwives and general
practitioners. Moreover, screening for gestational diabetes mellitus
(GDM) was done with fasting glucose measurements in woman who
were obese, had a family history of diabetes mellitus, GDM in a previ-
ous pregnancy, a previous delivery of an infant above 4,500g, previous
stillbirth, age above 38 years, or glucosuria in the current pregnancy.
When two independent fasting capillary plasma glucose values were
above 4.6 mmol/l, the woman was referred to an OGTT.
Offspring follow-up
During 2008 and 2009, mothers and offspring were contacted and
offspring invited to answer a web-based questionnaire, including
inquiries on current health and lifestyle. For instance, they were
asked how many hours per day, on a typical weekday, they were
physically active. Possible answers were a) more than 3 h per day,
b) 2-3 h per day, c) 1-1.5 h per day, d) 0-0.5 h per day, e) none,
and f) don’t know. The question was repeated for a typical Sunday.
From these two questions, a combined variable with four levels of
activity, covering physical activity during the whole week, was
created.
All potential participants were asked to participate in a clinical
examination. The participants were examined between 8:00 AM and
12:30 PM after an overnight fast. Height, weight, and waist circum-
ference were measured. After 7 min of rest, blood pressure was
measured three times in the horizontal position using an automatic
blood pressure device (OMRON M6 Comfort HEM-7000-E). The
average value of the last two measurements was used in the analy-
ses. A venous blood sample was drawn and immediately centrifuged
and frozen at 280

C.
From a total number of 965 women, we traced 894 offspring. The
mother–offspring dyads that were not traced consisted of mothers
and children with an incorrect personal identification number, moth-
ers, and children, who had died or were abroad, or with unknown
addresses. A total of 684 subjects (77% of the eligible population)
participated in the follow-up study by filling out the questionnaire,
providing information on the offspring’s level of physical activity.
Of these 439 attended the clinical examination and constituted the
study population.
Exposure variables
Analyses of the biomarkers from third trimester of pregnancy were
done on frozen serum samples in a central laboratory at Department
of Internal Medicine and Cardiovascular Research Institute Maas-
tricht, Maastricht University Medical Centre (by C.G.S). The possi-
bility of measuring biomarkers on the 20-year-old serum samples
was first tested in a pilot study on nine representative samples. The
serum concentration (mean [6SD]) of CRP was 2.1 (62.0) mg/ml,
of IL-6 1.8 (62.0) pg/ml, and of TNF-a 6.6 (62.4) pg/ml, respec-
tively. Furthermore, IL-1b was measured in all the serum samples at
a mean concentration of 0.6 (60.5) pg/ml. As reference value, we
used data of The Amsterdam Growth and Health Longitudinal Study
(AGAHLS). The AGAHLS is a longitudinal cohort study initiated in
1977. Details have been described elsewhere (27). Plasma bio-
markers in blood samples from follow-up examinations were deter-
mined after storage of serum samples during 10 years at 280C.
Only data of women (36 years, n5 199) was used as reference in
pilot study. In these women, the concentration of CRP (median
[IQR]) was 0.9 (0.4-2.9) mg/ml, of IL-6 2.4 (1.6-3.9) pg/ml, and of
TNF-a (mean6 SD) 9.06 3.1 pg/ml, respectively. From this pilot
study, we concluded that we were able to measure CRP, TNF-a, IL-
1b, and IL-6 in serum samples obtained in gestational week 30 after
20 years of storage, and that the absolute serum levels of CRP,
TNF-a, and IL-6 in serum samples were comparable with measure-
ments done on samples which were stored for 10 years at 280C.
Concentrations of CRP, TNF-a, IL-6, and IL-1b were measured by
4-plex multiarray electrochemiluminescense detection platforms of
MesoScaleDiscovery (MesoScaleDiscovery, Gaithersburg, MD,
USA, www.mesoscale.com) (28). This system uses multiarray plates
fitted with multielectrodes per well with each electrode being coated
with a different capture antibody. For the present study, two 4-plex
assays (plates fitted with four electrodes per well, i.e., four separate
well spots with a different capture antibody bound to each) was
used and we selected data of CRP, TNF-a, IL-6, and IL-1b. The
assay procedure follows that of a classic sandwich ELISA with any
of the analytes of interest captured on the relevant electrode. These
captured analytes were, in turn, detected by a secondary, analyte-
specific, ruthenium-conjugated antibody, which is capable of emit-
ting light after electrochemical stimulation. This method minimizes
nonspecific signals as the stimulation mechanism (electricity) is
decoupled from the signal (light). Each sample was analyzed in
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duplicate on the same array plate. The intra- and interassay coeffi-
cients of variation (CV) for the platform of MSD were, for CRP,
4.6% and 5.8%; for TNF-a: 4.5% and 8.5%, for IL-6: 6.0% and
15.6%, and for IL-1b: 13.3% and 18.0%. The variables were ana-
lyzed as continuous variables and as supplementary analyses in
quintiles based on the samples of all women in the cohort (n5 894).
Outcome markers for MS
Primary outcome variables were chosen among the continuous varia-
bles inherent in the definition of MS, i.e., waist circumference (cm),
fasting levels of plasma glucose (mmol/l), triglycerides (mmol/l),
and HDL cholesterol (mmol/l), as well as systolic and diastolic
blood pressure measurements (mm Hg). In addition, the primary out-
come variables were supplemented with secondary variables associ-
ated with MS, including BMI (kg/m2), plasma levels of LDL and
total cholesterol (mmol/l), concentrations of fasting plasma insulin
(pmol/l), and leptin (mg/l), as well as HOMA-IR. Waist circumfer-
ence and BMI were determined solely by means of data from the
clinical examinations (439 subjects) to eliminate the possibility of
under-reported data on BMI and waist circumference.
Offspring biomarkers
Offspring biomarkers were all measured in Denmark. Blood samples
were obtained during 2008 and 2009 and immediately frozen at
280C. Plasma glucose was measured during the examination
immediately after blood sampling using bedside equipment. Serum
triglycerides and cholesterol fractions (total cholesterol, LDL, and
HDL) were continuously measured according to standard methods at
Aalborg Hospital in several rounds until the beginning of 2010.
Insulin, leptin, and adiponectin were analyzed at the Medical
Research Laboratories, Aarhus University Hospital in January 2010.
Serum leptin concentrations were determined by a time-resolved
immunofluorometric assay based on commercially available reagents
and recombinant human leptin as standard (29). Plasma insulin con-
centrations were determined using a commercial ELISA kit. Insulin
resistance was estimated using the homeostasis model assessment
for insulin resistance (HOMA-IR) by means of the formula: fasting
glucose (mmol/l) 3 fasting insulin (mU/l)/22.5 (30).
Statistical analyses
Baseline characteristics of pregnant women either with participating
or nonparticipating offspring were tested for differences by v2 test.
Median levels of maternal biomarkers were tested for trends across
covariate categories using Kruskal–Wallis test. Associations between
maternal levels of biomarkers and offspring outcome variables were
examined by multivariate linear regression analyses. Waist circum-
ference was adjusted for BMI using the residual method (31), which
provides a measure of waist circumference uncorrelated with BMI.
Owing to skewed distributions, all outcome variables except
adjusted waist circumference and blood pressure were log-
transformed.
We a priori decided to include the following covariates: maternal
height (continuous, 3% missing), education (five categories, 5%
missing), smoking (yes or no, 5% missing), and prepregnancy BMI
(continuous, 3% missing). All maternal biomarker measurements
were above detection levels. Three outliers among the biomarkers
(CRP 112 mg/l; Il-6 60 pg/ml, and Il-1b 18 pg/ml) were
excluded from the analyses as well as observations with missing
covariate values (n5 50 [11%]).
Maternal height and prepregnancy BMI were included as these vari-
ables are possible determinants of anthropometric and metabolic
measures in the offspring. Maternal education and smoking were
included to account for potential social and lifestyle confounding.
As a supplementary analysis, imputation of missing values (n5 50)
was used to test if the same conclusion could be reached with
TABLE 1 Characteristics of pregnant women in the birth
cohort dependent on their offspring’s participation in the
follow-upa
Mothers with
nonparticipating
offspring (n5 526)
Mothers with
participating
offspring (n5439)
Percent Percent P value
Height (cm) 0.90
2159 8 8
160-164 21 21
165-169 35 33
170-174 24 27
175- 12 12
Education 0.002
None 18 12
Vocational 28 23
Bachelor 40 44
Academic 14 20
BMI (kg/m2) 0.51
<18.6 11 9
18.6 to <25 78 82
25 to <30 7 6
30- 4 3
Smoking 43 37 0.09
Nulliparous 56 60 0.19
CRP 0.07
Lowest quintile 20 20
Mid quintile 20 21
Highest quintile 23 17
TNF-a 0.82
Lowest quintile 20 20
Mid quintile 19 21
Highest quintile 21 19
IL-6 0.62
Lowest quintile 20 20
Mid quintile 21 19
Highest quintile 21 19
IL-1b 0.67
Lowest quintile 20 19
Mid quintile 20 21
Highest quintile 22 18
aDifferences between the two groups of women are reported as P value from v2
test for measure of association.
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increased statistical power. Missing values on the continuous varia-
bles were imputed by median imputation, while missing values on
the categorical variables were imputed by mode imputation. For
maternal BMI and height, we thus used the medians 20.9 kg/m2 and
168 cm, and for smoking and education we used the most frequent
observation, which was ‘no’ and ‘other education’. Furthermore, to
unmask potential associations between maternal inflammatory
markers and metabolic outcomes in the offspring that might be con-
founded by maternal BMI and smoking, we conducted supplemen-
tary analyses with maternal prepregnancy BMI and smoking
excluded from the statistical model. These results are included in
Table 3. In addition, two supplementary analyses were conducted
with offspring physical activity and BMI, respectively, included in
the model to eliminate the possible influence by these determinants
on the levels of offspring MS markers and thus to reduce the var-
iance of the outcome variables. Moreover, exposure levels in women
diagnosed with GDM were compared with healthy pregnant women.
A preliminary test for interaction of sex showed significant interac-
tion with several, but not all of the studied associations. Therefore,
the statistical analyses were performed for all offspring, while
adjusting for offspring sex, and subsequently also for males and
females separately to investigate potential differences between the
sexes. Changes in outcome variables for 5 units increment in levels
of IL-6, and IL-1b and for 10 units increment in TNF-a and CRP
are presented as absolute changes for waist circumference and blood
pressure and as relative changes for BMI and biomarkers. These
measures of association are expressed as ‘difference per 5 units
increment (95% CI)’ and ‘ratio per 5 units increments (95% CI)’,
respectively, and equivalent for 10 units increment. Associations
were considered statistically significant at the 5% level. All analyses
were performed using the SAS GLM procedure (Version 9.3; SAS
Institute, Cary, NC).
Results
Mothers of participating offspring were more often normal weight
and nonsmokers and had a higher education compared with mothers
of nonparticipating offspring (Table 1). Participation was not associ-
ated with the levels of inflammatory markers. Higher prepregnancy
BMI was associated with higher levels of CRP and IL-6 and border-
line significantly associated with higher levels of TNF-a. Also,
higher levels of CRP were associated with lower education (Table
2). No significant associations were found with the other covariates
included in the model: maternal height and smoking, and the off-
spring’s sex.
Analyses of pairwise linear associations between the four biomarkers
were done by means of Spearman’s correlations. Apart from CRP
and IL-1b, the biomarkers were significantly correlated although the
strength of the correlations was rather modest (r  0.10-0.25).
In the analyses of biomarker levels in the pregnant women and
markers of MS in their offspring we found no associations with
either the primary or the secondary outcome variables (Table 3).
TABLE 2 Associations between maternal inflammatory markers and covariatesa
Covariate Category
Level of maternal inflammatory markers in each covariate category
CRP TNF-a IL-6 IL-1b
Median6
IQR P trend
Median6
IQR P trend
Median6
IQR P trend
Median6
IQR P trend
Maternal height (cm) 2159 2.66 3.4 0.77 4.96 2.9 0.34 1.16 0.6 0.77 0.46 0.3 0.23
160-164 3.36 4.8 5.66 2.5 1.16 0.7 0.56 0.5
165-169 2.96 3.6 5.56 3.2 1.26 0.9 0.56 0.5
170-174 2.96 3.2 5.86 3.0 1.16 0.7 0.56 0.5
175- 3.16 4.0 5.66 3.3 1.26 0.7 0.56 0.5
Prepregnancy BMI 1-18.5 2.16 3.2 <0.0001 5.46 3.1 0.06 1.16 0.6 0.02 0.56 0.6 0.39
18.6-24.9 2.96 3.4 5.56 2.9 1.16 0.8 0.56 0.5
25-29.9 5.26 9.5 5.76 3.0 1.26 0.8 0.66 0.5
30- 8.86 7.2 7.16 2.6 1.36 1.0 0.56 0.3
Maternal smoking No 2.86 3.7 0.12 5.76 3.2 0.32 1.16 0.7 0.05 0.56 0.5 0.54
Yes 3.36 3.8 5.66 2.7 1.26 0.8 0.56 0.5
Maternal education None 3.86 4.9 0.0001 5.86 3.3 0.31 1.26 1.0 0.54 0.56 0.5 0.66
Vocational 3.36 4.4 5.56 2.9 1.16 0.8 0.56 0.5
Bachelor 2.86 3.4 5.76 3.1 1.16 0.6 0.56 0.5
Academic 2.26 2.9 5.66 2.5 1.16 0.8 0.56 0.5
Offspring’s sex Male 3.06 3.6 0.45 5.76 3.1 0.28 1.16 0.7 0.76 0.56 0.5 0.23
Female 2.96 3.9 5.56 2.9 1.16 0.8 0.56 0.4
aTrends of mean levels of maternal inflammatory markers across covariates in categories are reported as P trend from Kruskal-Wallis test. Biomarker concentrations and
distributions according to covariates are based on all traced women in the cohort (n5894). Distribution of biomarker levels according to offspring sex is furthermore
restricted to the dyads, which include the 688 offspring answering the web-based questionnaire.
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The results did not show significant differences between crude asso-
ciations, associations adjusted by maternal smoking, and prepreg-
nancy BMI or associations fully adjusted for potential confounding.
However, higher levels of IL-6 were associated with lower systolic
blood pressure in the offspring (difference per 5 units increment in
IL-6 25.86 mm Hg [95% CI: 211.0, 20.74] in the fully adjusted
analysis). This association persisted in the subgroup of female off-
spring (difference 26.62 mm Hg [95% CI 212.4, 20.89]). How-
ever, supplementary analyses with the exposure variable in quintiles
did not show any associations, neither in the combined analyses nor
in analyses stratified by offspring sex (data not shown). No other
associations were detected in the combined analyses or in the sub-
group of females or males. These null findings were supported by
analyses of crude correlations (Spearman) between these inflamma-
tory markers and the offspring outcome variables (data not shown).
The supplementary analyses with imputation of missing values (data
not shown) or with maternal prepregnancy BMI and smoking
excluded from the statistical model (Table 3) did not lead to changes
in the results and neither did the adjustments for the offspring’s
ambient level of physical activity and BMI.
Among the 439 women included in the analyses, 11 (2.5%) were
diagnosed with GDM. There was a small tendency towards higher
levels of inflammatory markers in women with GDM than with no
GDM; however, the differences were not significant nor related to
offspring outcome variables.
Discussion
For the first time, we investigated whether markers of systemic sub-
clinical inflammation in third trimester of pregnancy may be associ-
ated with the offspring’s metabolic profile many years later. It is
well known that diabetes, obesity, and insulin resistance in the
mother are associated with inflammation, and that these metabolic
conditions affect the growth and development of the fetus to various
extents, with possible consequences for the future metabolic health
(14,32,33). However, it is unknown whether inflammatory markers
in healthy pregnant women are associated with MS in the offspring.
The four markers of inflammation analyzed in this study are all con-
sidered to play some role in metabolism and vascular functions, and
in particular TNF-a has been suggested as a possible central link
between obesity, impaired glucose tolerance and type 2 diabetes
(34). TNF-a has furthermore been suggested as a predictor of insulin
resistance in normal pregnancies (35).
Nevertheless, this study does not demonstrate evidence that markers
of low-grade inflammation in pregnancy are associated with any
measurable unfavorable metabolic profile in young adult offspring.
Four biomarkers of inflammation were carefully selected and studied
individually. The rationale for selecting these four inflammatory
markers was based on the knowledge of these markers being among
the most important mediators of inflammation and their association
with metabolic and vascular functions and diseases (20,35,36). To
this end, we speculated that they could have distinct and possibly
different roles in developmental programming of metabolism in the
offspring despite being interrelated. Besides, the statistically signifi-
cant association between higher maternal IL-6 levels and lower sys-
tolic blood pressure among female offspring only, none of the otherTA
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maternal inflammatory biomarkers turned out to be associated with
the individual markers of MS in the offspring. The unexpected asso-
ciation between IL-6 plasma levels in the mother and systolic blood
pressure in the offspring, observed when IL-6 was analyzed as a
continuous variable, did not show up in the additional analyses with
the levels of IL-6 divided into quintiles. Caution is warranted with
respect to over-interpretation of this result due to the risk of a false-
positive finding as a result of multiple comparisons. Indeed, the sig-
nificance disappeared after correction for the number of comparisons
performed.
The concentrations of the inflammatory markers measured in third
trimester of pregnancy were comparable to cited values in the litera-
ture (37-39). In the first trimester, pregnancy is characterized by a
proinflammatory phase, subsequently overtaken by an anti-
inflammatory state during the third trimester (17,18). Still, detailed
data on biomarker levels in third trimester of normal pregnancies
are sparse. Since circulating biomarkers of systemic subclinical
inflammation are highly dependent on factors, such as BMI, infec-
tions, smoking, medication, and alcohol consumption (40), the anal-
yses were adjusted for prepregnancy BMI and smoking. This adjust-
ment, however, did not affect the findings. Moreover, adjustment for
the offspring’s ambient level of physical activity and supplementary
analyses with the exposure variables in quintiles did not change the
results, which further supports the null findings of the study.
According to our a priori hypothesis, our clear null findings were
somewhat surprising. Thus CRP, TNF-a, and IL-6 were associated
with prepregnancy BMI (Table 2). However the women were gener-
ally healthy; thus, only 9% had a prepregnancy BMI 25 kg/m2,
and the observed levels of inflammatory markers were generally low
(Table 3). Furthermore, they did not differ significantly in the 11
women with GDM. Of course, we cannot exclude the possibilities;
first, that storage at 220C for 20 years may have caused some
degree of uncertainty to the measurement of exact levels of inflam-
matory markers, and secondly that the levels of inflammation in the
pregnant women were too low to affect the metabolic development
of their offspring. Regardless, subclinical inflammation is defined as
subtle elevations of inflammatory markers within or only slightly
above the normal range, supporting the biological relevance of the
negative findings in this well powered and indeed phenotypically
well characterized and extensive study material.
In conclusion, the results suggest that in a normal population of
pregnant women, markers of inflammation in third trimester are not
associated with markers of MS in offspring at the age of 20 years.
Although these data need further validation from other studies,
future studies should aim to identify other mechanisms linking sub-
clinical inflammatory states during pregnancy to adverse metabolic
outcomes in the offspring.O
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